You are here

  • Home
  • Online First
  • Treatments for macular degeneration: summarising evidence using network meta-analysis

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Letter
Treatments for macular degeneration: summarising evidence using network meta-analysis
  1. Valeria Fadda,
  2. Dario Maratea,
  3. Sabrina Trippoli,
  4. Andrea Messori
  1. Laboratorio SIFO di Farmacoeconomia, Area Vasta Centro Toscana, ESTAV, Prato, Italy
  1. Correspondence to Dr Andrea Messori, Laboratorio SIFO di Farmacoeconomia, c/o Area Vasta Centro Toscana, Regional Health System, Via Guimaraes 9-11, 59100 Prato, Italy; andrea.messori.it{at}gmail.com

https://doi.org/10.1136/bjophthalmol-2011-300316

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In studying treatments for age-related macular degeneration (AMD), randomised controlled trials have typically used placebo or verteporfin in the control group.1 2 Hence, information on direct head-to-head comparisons between the newest agents is still needed.

    Network meta-analysis (NMA) is a tool that summarises the information on comparative effectiveness when three or more treatments are proposed for the same clinical indication.3 4 NMA includes both direct comparisons (based on real trials) and indirect comparisons (based on statistical testing in the absence of a real head-to-head trial). The main advantage of NMA lies in its communicative value5; another advantage is that it overcomes one …

    View Full Text

    Footnotes

    • Competing interests None.